Clinical Trial of PCV24 in Adults Aged ≥18 Years

Summary

A Phase Ib/II clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24)developed by Sinovac Life Science Co., Ltd will be conducted in adults aged ≥18 years. The objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, Positive Controlled phase Ib/II clinical trial.

Timeline

Start

2025-06-18

Primary completion

2026-02-26

Completion

2026-02-26

Drugs

Indications